Automating Ancillary Processes: Closing The New Bottleneck In Cell and Gene Therapy Manufacturing

Manual media formulation and viral vector packaging are time-intensive, tedious, and expensive activities. While cell and gene therapy manufacturers focus on closing core manufacturing processes, ancillary processes such as media formulation and viral vector packaging may remain open. These open processes introduce challenges in a GMP setting such as a higher risk of contamination, increased processing time, process variability, low throughput and the necessity for higher room classification or isolators.

In this webinar, the speakers will share common and uncommon challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms. They will also discuss what industry standards could help to make large-scale media formulation and viral vector packaging more accessible to cell and gene therapy manufacturers.